Promises, Advances and Challenges
Offers a synthesis of the knowledge about diverse topics of the biomarker and endophenotype strategies in neuropsychiatry. This book is suitable for neuroscientists, psychiatrists, neurologists, endocrinologists, pharmacologists, clinical psychologists, general practitioners, and geriatricians.
Neuropsychiatric disorders such as schizophrenia, mood disorders, Alzheimer's disease, epilepsy, alcoholism, substance abuse and others are some of the most debilitating illnesses worldwide characterizing by the complexity of the causes, and lacking the laboratory tests that may promote diagnostic and prognostic procedures. Recent advances in neuroscience, genomic, genetic, proteomic and metabolomic knowledge and technologies have opened the way to searching biomarkers and endophenotypes, which may offer powerful and exciting opportunity to understand the etiology and the underlying pathophysiological mechanisms of neuropsychiatric disorders. The challenge now is to translate these advances into meaningful diagnostic and therapeutic advances. This book offers a broad synthesis of the current knowledge about diverse topics of the biomarker and endophenotype strategies in neuropsychiatry.; The book is organized into four interconnected volumes: "Neuropsychological Endophenotypes and Biomarkers" (with overview of methodological issues of the biomarker and endophenotype approaches in neuropsychiatry and some technological advances), "Neuroanatomical and Neuroimaging Endophenotypes and Biomarkers", "Metabolic and Peripheral Biomarkers" and "Molecular Genetic and Genomic Markers". The contributors are internationally and nationally recognized researchers and experts from 16 countries. This four-volume handbook is intended for a broad spectrum of readers including neuroscientists, psychiatrists, neurologists, endocrinologists, pharmacologists, clinical psychologists, general practitioners, geriatricians, health care providers in the field of neurology and mental health interested in trends that have crystallized in the last decade, and trends that can be expected to further evolve in the coming years. It is hoped that this book will also be a useful resource for the teaching of psychiatry, neurology, psychology and mental health.
ForewordContributors Part I. Methodological and Technological Advances1. Where do we stand in the quest for neuropsychiatric biomarkers and endophenotypes and what next? Michael S. Ritsner and Irving I. Gottesman2. Methodological and statistical issues in the use of biomarkers in clinical and research studies. Ryan Van Lieshout and Peter Szatmari3. Challenging the genetic complexity of schizophrenia by use of endophenotypes. Assen Jablensky4. Translational medicine: functional biomarkers for drug development of "cognitive enhancers" in schizophrenia. Georg Winterer5. Leveraging high-dimensional neuroimaging data in genetic studies of neuropsychiatric disease. Cinnamon S. Bloss, Trygve E. Bakken, Alexander H. Joyner, Nicholas J. Schork6. Proteomics as a new tool for biomarker-discovery in neuropsychiatric disorders. Thomas J. Raedler, Harald Mischak, Holger Jahn, Klaus Wiedemann7. Schizophrenia endophenotypes as treatment targets. Stephen I. Deutsch, Barbara L. Schwartz, Richard B. Rosse, John Mastropaolo, Ayman H. Fanous, Abraham Weizman, Jessica A. Burket, Brooke L. Gaskins Part II. Neuropsychological, Neurocognitive and Neurophysiological Domains8. Neuropsychological endophenotypes in schizophrenia and bipolar I disorder: yields from the Finnish family and twin studies. Annamari Tuulio-Henriksson, Jonna Perala, Irving I. Gottesman and Jaana Suvisaari9. Is more cognitive experimental psychopathology of schizophrenia really necessary? Challenges and opportunities. Angus MacDonald, III10. Intellectual functioning as an endophenotype for schizophrenia. Odette de Wilde11. Emotion recognition deficits as a neurocognitive marker of schizophrenia liability. Renata Schoeman, Dana J. H. Niehaus, Liezl Koen, Jukka M. Leppanen12. The use of neurocognitive endophenotypes in large-scale family genetic studies of schizophrenia. William P. Horan, Tiffany A. Greenwood, David L. Braff, Raquel E. Gur and Michael F. Green13. Neurocognitive endophenotypes for bipolar disorder: evidence from case-control, family and twin studies. Eugenia Kravariti, Fergus Kane, Robin Murray14. Trait and state markers of schizophrenia in visual processing. Yue Chen, Daniel Norton and Ryan McBain15. Visual scanning abnormalities as biomarker for schizophrenia and bipolar disorder. Patricia E. G. Bestelmeyer16. Biomarkers and endophenotypes in eating disorders. Carolina Lopez, Marion Roberts and Janet Treasure17. Movement abnormalities: a putative biomarker of risk for psychosis. Vijay Mittal and Elaine Walker Afterword by Robert H. BelmakerContents of Volumes 2, 3, and 4Contributors of Volumes 2, 3, and 4Index